Osu-03012, A Novel Celecoxib Derivative, Induces A Unique Autophagy-Like Cell Death In Human Hepatocellular Carcinoma Cells
ming gao,peiyen yeh,chihhung hsu,jenmin feng,chingshih chen,minliang kuo,annlii cheng
IF: 11.2
2006-01-01
Cancer Research
Abstract:Proc Amer Assoc Cancer Res, Volume 47, 2006 4662 Hepatocellular carcinoma (HCC) is one of the most common and lethal solid tumors in the world. HCC is typically refractory to almost all cytotoxic chemotherapeutic agents. OSU-03012 is a derivative of celecoxib, a cyclooxygenase (COX)-2 inhibitor. However, its primary mechanism of action is known as 3-phosphoinositide-dependent kinase-1 (PDK-1) inhibition and by which it induces apoptosis in certain cancer cells[Zhu J et al. , Cancer Res. 64:4309-18, 2004; Hsu AL et al. , J Biol. Chem . 275:11937-403. 2000]. This study sought to investigate if OSU-03012 may be effective in the treatment of HCC. OSU-03012 inhibited cell growth of Huh7, a human HCC cell line, in a dose-dependent manner, with IC50 at 1μM, which is well below the non-toxic serum concentration (5-20μM) in mice. Surprisingly, in this Huh7 cell model, western blotting analysis demonstrated that neither pPDK1 nor pAkt was suppressed by OSU-03012. Cell cycle analysis by flow cytometry indicated that OSU-03012 (5μM, 24h) significantly increased S-phase population, while did not alter sub-G1 population, suggesting that apoptosis is not a major mechanism of cell growth suppression. Western blotting analysis showed that OSU-03012 reduced protein level of cyclin D1. Furthermore, OSU-03012-treated cells exhibited cytoplasmic vacuoles which were positively stained by acridine orange and monodansylcadaverine, a phenomenon mimicking cell autophagy. The content in the OSU-03012-induced autophagosomes and its mechanistic linkage with the occurrence of autophagy-like cell death of Huh7 cells are under investigation. Together, our preliminary results indicate that OSU-03012 might be an effective therapeutic agent for HCC, but the mechanisms of action of this drug in HCC cells need to be further clarified. (This study was supported by grant DOH94-TD-B-111-001 from Department of Health, R.O.C. to National Clinical Research Center at National Taiwan University)